Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

NCT00794781 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00794781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00794781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2008
Completion date
October 15, 2015
Enrollment
55 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors